Latest data updates for Cancer Breakthroughs Tracker.https://watchboard.dev/en-ushttps://watchboard.dev/cancer-breakthroughs/#digest-2026-06-09/https://watchboard.dev/cancer-breakthroughs/#digest-2026-06-09/GSK acquires Nuvalent, maker of targeted lung cancer drugs (zidesamtinib, neladalkib), for $10.6B — major consolidation in precision oncology.Tue, 09 Jun 2026 00:00:00 GMTbreakinghttps://watchboard.dev/cancer-breakthroughs/#digest-2026-06-07/https://watchboard.dev/cancer-breakthroughs/#digest-2026-06-07/ASCO 2026 (May 29–June 2, Chicago) delivered a historically dense set of breakthrough results. The daraxonrasib RASolute 302 Phase 3 trial — received with a standing ovation at the ASCO Plenary and simultaneously published in The New England Journal of Medicine — nearly doubled overall survival in metastatic pancreatic cancer (HR 0.40; 13.2 vs. 6.7 months), proving RAS is druggable after 40 years of failure; FDA expanded access is now open. Five-year KEYNOTE-942 data confirmed intismeran autogene (mRNA-4157) sustains a 49% reduction in melanoma recurrence at 5 years (HR 0.51; JCO). Adjuvant selpercatinib (LIBRETTO-432, NEJM) cut recurrence risk by 83% in RET fusion-positive early lung cancer. Sacituzumab tirumotecan (OptiTROP-Lung05, The Lancet) became the first ADC+IO combination to outperform pembrolizumab monotherapy in Phase 3 first-line NSCLC. Ivonescimab became the first China-originated drug ever selected for the ASCO Plenary in 61 years of the organization's history. Post-ASCO, Mayo Clinic's AI model for pancreatic cancer detection up to 3 years pre-diagnosis reinforces the convergence of early detection and targeted therapy in PDAC.Sun, 07 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-06-03/https://watchboard.dev/cancer-breakthroughs/#digest-2026-06-03/FDA Approves First Generic Eribulin Mesylate (Lupin/Natco), Expanding Access to Halichondrin-Class Therapy for Metastatic Breast Cancer and Liposarcoma. ASCO 2026 Post-Meeting Analysis: Chinese and Asian Pharma Emerge as First-in-Class Leaders — ivonescimab First China-Originated Drug at ASCO Plenary in 61-Year History.Wed, 03 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-06-02/https://watchboard.dev/cancer-breakthroughs/#digest-2026-06-02/FDA Grants Fast Track Designation to Giredestrant for Early-Stage ER+/HER2- Breast Cancer Following ASCO lidERA Data. ASCO 2026: OrigAMI-4 Phase 2 — Amivantamab Achieves 42% Response Rate in Checkpoint-Refractory Head and Neck Cancer. ASCO 2026: RAD-IO Phase 2 — Adding Durvalumab to Chemoradiotherapy Achieves 84% Disease-Free Survival at 1 Year in Muscle-Invasive Bladder Cancer, Avoiding Surgery.Tue, 02 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-06-01/https://watchboard.dev/cancer-breakthroughs/#digest-2026-06-01/In what many oncologists called the most consequential cancer trial result of the decade, the Phase 3 RASolute 302 trial — presented at the ASCO 2026 Plenary Session by Dr. ASCO 2026 Plenary: LIBRETTO-432 — Adjuvant Selpercatinib Reduces Recurrence Risk by 83% in RET Fusion-Positive Early Lung Cancer (NEJM). The Phase 3 PROTEUS trial, presented by Dr. ASCO 2026: mRNA-4157/V940 (Intismeran Autogene) 5-Year Data — Personalized mRNA Cancer Vaccine Sustains 49% Reduction in Melanoma Recurrence at 5 Years (JCO).Mon, 01 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-31/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-31/ASCO 2026 & The Lancet: OptiTROP-Lung05 Phase 3 — Sacituzumab Tirumotecan + Pembrolizumab Reduces Lung Cancer Progression by 65% vs. Pembrolizumab Alone. ASCO 2026: lidERA BC Phase 3 — Giredestrant Oral SERD Reduces Breast Cancer Recurrence by 30% in Early ER+/HER2- Disease. The Phase 3 VIKTORIA-1 trial (Abstract LBA1008), presented at ASCO 2026 by Dr.Sun, 31 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-30/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-30/ASCO 2026: SARC041 Plenary — Abemaciclib Reduces Liposarcoma Progression Risk by 62%, First Positive Phase 3 Result Ever in Dedifferentiated Liposarcoma. ASCO 2026: OPTIMA Phase 3 — Genomic Testing Allows 68% of Breast Cancer Patients to Safely Skip Chemotherapy Without Worse Outcomes. ASCO 2026: SUCCESSOR-2 Phase 3 — Mezigdomide + Carfilzomib Halves Disease Progression in Heavily Pretreated Multiple Myeloma.Sat, 30 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-29/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-29/ASCO 2026 opened in Chicago with multiple landmark presentations. The CROWN trial's 7-year lorlatinib update showed approximately 60% of ALK+ NSCLC patients progression-free at 5 years with 92% CNS protection — among the most remarkable outcomes in targeted lung cancer therapy. The HARMONi-6 Phase 3 trial demonstrated ivonescimab, a dual PD-1/VEGF bispecific antibody, achieves 11.1 vs. 6.9 months PFS over anti-PD-1 alone in squamous NSCLC. Dana-Farber reported 100% MRD-negativity in all 20 patients with high-risk smoldering myeloma treated with CAR-T. On May 28, the NEJM published ASCENT-03 confirming sacituzumab govitecan superiority over chemotherapy in PD-1-ineligible TNBC. The FDA approved Decnupaz (pivekimab sunirine) on May 27 for BPDCN, bringing 2026 oncology approvals to 15+. The daraxonrasib Phase 3 pancreatic cancer plenary is scheduled for May 31.Fri, 29 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-28/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-28/AACR Editors' Picks: CAR-T Therapy Advances and Neuron-Tumor Crosstalk in Pancreatic Cancer Highlighted. NEJM Publishes ASCENT-03: Sacituzumab Govitecan Improves PFS in PD-1-Ineligible Advanced TNBC.Thu, 28 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-27/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-27/FDA Approves Decnupaz (Pivekimab Sunirine) for Rare Blood Cancer BPDCN — 15th Oncology Approval of 2026.Wed, 27 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-22/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-22/Two landmark FDA approvals on May 15 reshaped the cancer treatment landscape: Enhertu (T-DXd) became the first antibody-drug conjugate approved for early-stage curative-intent HER2+ breast cancer in both neoadjuvant and adjuvant settings, while atezolizumab (Tecentriq) became the first immunotherapy selected by liquid biopsy, approved for ctDNA-positive muscle-invasive bladder cancer after cystectomy. ASCO 2026 released its full embargo of 7,000+ abstracts on May 21 — the largest in the meeting's history — unveiling Phase 3 data from BREAKWATER (BRAF V600E colorectal), VIKTORIA-1 (PIK3CA breast), and EV-302 (bladder perioperative). Olverembatinib + blinatumomab data from Ascentage Pharma showed 91.3% complete cytogenetic response in relapsed CML at ASCO. The plenary daraxonrasib Phase 3 pancreatic cancer readout is scheduled for May 31.Fri, 22 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-21/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-21/ASCO 2026 Lifts Embargo on 7,000+ Abstracts — BREAKWATER, VIKTORIA-1, EV-302 Phase 3 Data Unlocked.Thu, 21 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-15/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-15/The FDA approved sonrotoclax (Beqalzi) on May 13 as the first BCL-2 inhibitor specifically targeting relapsed/refractory mantle cell lymphoma after BTK inhibitor failure, with 52% overall response rate and 15.8-month median duration of response in 103 patients — addressing a critical unmet need in BTK-resistant MCL. On May 8, Bizengri (zenocutuzumab) received accelerated approval for NRG1 fusion-positive bile duct cancer, extending the bispecific HER2/HER3 antibody's pan-tumor reach to three NRG1+ cancer types. The FDA also granted Breakthrough Therapy Designation to emiltatug ledadotin (ADC) for adenoid cystic carcinoma on May 12 — one of the most promising early targeted therapy candidates for this rare, incurable salivary gland malignancy. Additionally, the liquid biopsy field's resolution section has been updated to reflect the February 2026 NHS-Galleri trial miss (primary endpoint not met), adding context for the ongoing debate over MCED screening readiness. ASCO 2026 full abstracts release on May 21, with daraxonrasib's Phase 3 plenary on May 31.Fri, 15 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-13/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-13/FDA Approves Sonrotoclax (Beqalzi) for Relapsed/Refractory Mantle Cell Lymphoma — First BCL-2 Inhibitor Approved Specifically for MCL.Wed, 13 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-12/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-12/FDA Grants Breakthrough Therapy Designation to Emiltatug Ledadotin for Adenoid Cystic Carcinoma — Rare Salivary Gland Cancer With No Approved Targeted Therapies.Tue, 12 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-08/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-08/FDA Approves Zenocutuzumab (Bizengri) for NRG1 Fusion-Positive Bile Duct Cancer — First Targeted Therapy for This Oncogenic Driver.Fri, 08 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-07/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-07/The world's first PROTAC protein degrader drug, Veppanu (vepdegestrant), received FDA approval on May 1 for ESR1-mutant ER+/HER2- metastatic breast cancer — inaugurating a new therapeutic class that destroys the estrogen receptor rather than blocking it. The FDA simultaneously authorized expanded access for daraxonrasib in pancreatic cancer following Phase 3 data showing 13.2 vs. 6.7 months median OS. Daraxonrasib's Phase 1/2 results were published in NEJM on May 6 (30% response rate at 300 mg). Additional developments include a JACR study showing AI mammography triage captures 50% of screen-detected cancers in the top 2% of scans, and a Mount Sinai Cell Reports Medicine paper demonstrating that quad-target immunotherapy (PD-1+CTLA-4+LAG-3+TREM2) overcomes checkpoint resistance in treatment-refractory colorectal cancer.Thu, 07 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-06/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-06/Daraxonrasib Phase 1/2 Results Published in NEJM: 30% Response Rate in RAS-Mutant Metastatic Pancreatic Cancer.Wed, 06 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-05/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-05/Mount Sinai Study: Quad-Target Immunotherapy Combo Overcomes Resistance in Treatment-Refractory Colorectal Cancer.Tue, 05 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-02/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-02/AI Mammography Triage Captures 50% of Screen-Detected Cancers in Top 2% of Scans — JACR Study.Sat, 02 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-05-01/https://watchboard.dev/cancer-breakthroughs/#digest-2026-05-01/FDA Approves Veppanu (Vepdegestrant): World's First PROTAC Drug for ESR1-Mutant Breast Cancer. FDA Authorizes Expanded Access to Daraxonrasib After Unprecedented Phase 3 Survival Data in Pancreatic Cancer.Fri, 01 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-30/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-30/AACR 2026 follow-up delivered multiple landmark results this week. CAR-PRISM Phase 2 showed Carvykti achieving 100% MRD negativity in all 20 smoldering myeloma patients. NEOPRISM-CRC reported zero relapses at 33 months with pembrolizumab-only pre-surgery approach for MSI-high bowel cancer. ASCENT-04/KEYNOTE-D19 (NEJM) demonstrated Trodelvy + Keytruda outperforming chemo + immunotherapy in first-line PD-L1+ advanced TNBC (PFS 11.2 vs 7.8 months). Additional developments include MK-2010 bispecific (55% ORR in NSCLC), FDA Priority Review for PADCEV + Keytruda in perioperative bladder cancer, and today's FDA AdCom review of camizestrant for ESR1-mutant breast cancer.Thu, 30 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-28/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-28/FDA Grants Priority Review to PADCEV + Keytruda for Perioperative Muscle-Invasive Bladder Cancer.Tue, 28 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-26/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-26/Merck's MK-2010 PD-1/VEGF Bispecific Shows 55% Response Rate in First-Line NSCLC at AACR 2026.Sun, 26 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-25/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-25/ASCENT-04: Trodelvy + Keytruda Beats Chemo + Immunotherapy as First-Line Treatment in Advanced TNBC.Sat, 25 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-24/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-24/NEOPRISM-CRC Trial: Zero Bowel Cancer Relapses at 33 Months With Pre-Surgery Pembrolizumab Alone.Fri, 24 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-23/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-23/Carvykti CAR-T Achieves 100% MRD Negativity in High-Risk Smoldering Multiple Myeloma (CAR-PRISM Phase 2).Thu, 23 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-22/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-22/Revolution Medicines presents additional strong Phase 2 data on its KRAS inhibitor for pancreatic cancer at AACR 2026, along with a glimpse of a potential next-generation compound class beyond currentWed, 22 Apr 2026 00:00:00 GMTbreakinghttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-14/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-14/UT MD Anderson unveils latest cancer research breakthroughs at AACR conferenceTue, 14 Apr 2026 00:00:00 GMTbreakinghttps://watchboard.dev/cancer-breakthroughs/#digest-2026-04-13/https://watchboard.dev/cancer-breakthroughs/#digest-2026-04-13/GSK advances ovarian cancer drug mo-rez through clinical pipeline with positive momentum. FDA issues second rejection of Replimune's cancer drug while Revolution Medicines' pancreatic cancer pill continues to advance.Mon, 13 Apr 2026 00:00:00 GMTbreaking